Nuwellis, Inc. Common Stock
NUWENuwellis, Inc. (NUWE) is a medical device company focused on developing and commercializing innovative solutions for fluid management, primarily in critical care and dialysis markets. The company specializes in hemodialysis and ultrafiltration therapies, offering products designed to improve patient outcomes and streamline treatment protocols.
Company News
Nuwellis has signed a non-binding letter of intent to acquire Rendiatech, an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies, potentially expanding its fluid management technology platform.
Nuwellis held a Special Meeting of Stockholders, where shareholders approved proposals to increase authorized shares, potentially conduct a reverse stock split, and issue shares from a recent financing to enhance financial flexibility.
Nuwellis Inc experienced a dramatic 200% stock surge in premarket trading after receiving a new U.S. patent for an improved extracorporeal blood filtering machine that enhances fluid balance calculation accuracy in continuous renal replacement therapy systems.
Nuwellis experienced a significant stock price surge of 31.25% in after-hours trading following the announcement of securing a key patent for its fluid management technology and bringing back veteran CEO John Erb.
Nuwellis reported a 3% increase in revenue for Q1 2025, driven by growth in consumables utilization and higher U.S. console sales. The company also saw a 38% year-over-year increase in pediatric revenue and a 31% reduction in operating expenses.
